At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
ADIL Adial Pharmaceuticals
Market Closed 04-10 16:00:00 EDT
1.57
+0.01
+0.64%
盘后1.55
-0.02-1.27%
19:57 EDT
High1.59
Low1.54
Vol48.05K
Open1.59
D1 Closing1.56
Amplitude3.21%
Mkt Cap2.24M
Tradable Cap2.06M
Total Shares1.43M
T/O75.16K
T/O Rate3.67%
Tradable Shares1.31M
P/B--
ROE--
EPS0.00
52wk High--
52wk Low--
P/E--
Dividend--
Div.Yield--
ROA--
Loading ...
Adial Pharmaceuticals Implements New Executive Equity Compensation Plan
Adial Pharmaceuticals Signs an Exclusive Ad04 Collaboration Framework With Molteni Farmaceutici for Europe Which Anticipates Nearly $60 Million in Potential Royalties and Milestones Upon Execution of a Definitive Agreement
Adial Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment or prevention of addiction and related disorders. The company's lead product is AD04, a serotonin-3 antagonist, which is in Phase 3 clinical trials for the treatment of alcohol use disorder. It is also involved in the development of drug candidates for non-opioid pain reduction and other diseases and disorders. The company was founded in 2010 and is based in Glen Allen, Virginia.